CBD, or cannabidiol, comes from the hemp plant, a close relative to another member of the cannabis family, marijuana. Both plants contain abundant types of cannabinoids, but marijuana is high in the psychoactive chemical THC, while hemp is rich in CBD, the non-psychoactive component of cannabis that has generated quite a buzz for its potential medicinal benefits.

CBD has been touted as a treatment for a wide range of conditions — including anxiety, pain, inflammation and even cancer — but little reliable research has been done on CBD’s effects on humans, experts say. The only FDA-approved CBD oil is Epidiolex, an oral solutionprescribed for the treatment of seizures associated with two rare, severe forms of epilepsy.

“Societies have jumped far far ahead of science,” said Dr. Margaret Haney, a professor of neurobiology at Columbia University Medical Center and director of Columbia’s Marijuana Research Laboratory. “So it’s showing up in lotions and pretty much any form of product one can use. There’s a lot of different ways one could use CBD, but the ways we have studied CBD is much more limited.”

CVS has at least 9,800 stores nationwide and will soon roll out the CBD products in over 800 stores in the eight states. The health care chain says that effectiveness claims will vary from product-to-product, but that the company does not plan to market any of the items as a ‘cure-all’ product.

“We’re going to walk slowly, but this is something we think our customers will be looking for,” CVS Health CEO Larry Merlo said in an interview Wednesday with CNBC’s Jim Cramer.

Related

HEALTH

Daily use of high potency marijuana linked to higher rates of psychosis, study finds

The company noted that they would not be selling any CBD-based supplements or food additives. Under the Federal Food, Drug, and Cosmetic Act, it is illegal to introduce drug ingredients like CBD into the food supply or to market them as dietary supplements.

“Selling unapproved products with unsubstantiated therapeutic claims is not only a violation of the law, but also can put patients at risk, as these products have not been proven to be safe or effective,” FDA Commissioner Scott Gottlieb said in a statement in December.

For this reason, CVS will market the creams and salves as over-the-counter medicinal products, merchandised in a dedicated display.

There have been more dangerous situations where people turn down effective medications to use unproven products, like CBD.

To assure accurate labeling and safety for customers, CVS has partnered with Eurofins, a third party laboratory, to test all CBD topicals for THC, CBD content, and other contaminants, DeAngelis said in the statement to NBC News.

“We are working only with CBD product manufacturers that are complying with applicable laws and that meet CVS’s high standards for quality. Only products passing these independent tests are offered for sale in our stores,” the statement said.

Some experts believe the move by CVS to sell CBD over-the-counter may provide more questions than answers, at least initially.

“It’s a way to reduce the stigma for a product that really doesn’t deserve to be stigmatized,” said nutritionist and cannabis practitioner Brooke Alpert. “On the other hand, because of the lack of regulation it raises questions like: do people really know what they’re getting; can other brands get away with selling inferior products; and where can people find more information about these products?”

Related

HEALTH

FDA approves cannabis-based drug CBD for epilepsy

Another big concern for experts is that patients will avoid proven medications in favor of CBD.

“There have been more dangerous situations where people turn down effective medications to use unproven products, like CBD,” said Haney.

CBD-infused sprays, roll-ons, creams and salves will be offered as an ‘alternative source of relief’.

CVS to sell CBD-infused products

MARCH 21, 201901:26March 21, 2019, 5:26 PM EDTBy Shamard Charles, M.D.

CVS Pharmacy announced Wednesday that it will begin selling hemp-derived CBD products in eight states. The national drug store chain will be marketing the topical cannabidiol products, such as creams, sprays and roll-ons, as “an alternative source of relief,” CVS said in a statement to NBC News. CVS will also be partnering with a company to test and verify the quality of the CBD topicals sold in its drug stores.

“We are carrying hemp-derived CBD products in select states to help meet consumer demand for alternative care options,” said CVS Health Spokesperson, Mike DeAngelis.

The items will be sold in Alabama, California, Colorado, Illinois, Indiana, Kentucky, Maryland and Tennessee.

Detroit Free Press staffPublished 12:13 p.m. ET Jan. 25, 2019

A Michigan university said it will begin offering degrees in cannabis chemistry starting this fall — the first in the country.

Lake Superior State University in Sault Ste. Marie in the Upper Peninsula said the cannabis industry is projected to create more than 500,000 jobs by 2022 as more states legalize marijuana and cannabis-related products for recreational and medical use.

The average starting salary of a cannabis chemist is $72,000, the university said.

The program will offer associate and bachelor’s degrees in cannabis chemistry, which focuses on the quantitative analysis of cannabis-related compounds and contaminants. 

Students, who will use actual cannabis buds for analysis, may need to submit to a background check in order to participate in the program and in courses that handle regulated materials, as required by law.

Students who meet minimum standards may qualify for an American Chemical Society (ACS) degree.

Furloughed federal employees may be able to get up to an ounce of free pot.

headshot

By David Moye

It’s unknown when federal workers affected by the shutdown will be back at work, but there is one bit of good news: At least they can get some free pot.

A website called BudTrader.com, which bills itself as “the largest cannabis social media platform,” is offering to donate up to an ounce of the wacky weed to federal employees who are “unable to pay for their medical cannabis due to the Government shutdown,” according to a press release.

“I don’t think Federal employees are getting enough love and support, in these tough times, we want to extend the offer of a donation of medical cannabis to any Federal worker affected by the shutdown,” BudTrader CEO Brad McLaughlin said in the release. “We only hope our actions inspire larger companies to also try and help Federal employees affected by the shutdown.”

People who might qualify for the donations of dank should email support@budtrader.com.

A company spokesperson told HuffPost that federal employees need to show proof they have indeed been furloughed, and said BudTrader staffers are looking at social media pages for verification as well.

The website expects to fulfill any requests with the help of network of dispensaries all over North America.

In addition, the spokesperson said at least five cannabis doctors have offered to consult with furloughed federal employees who might need a medical marijuana prescription.

So far, federal employees aren’t exactly coming out of the weeds looking for free pot.

The spokesperson said only two federal employees have shown up at the company’s San Diego-area headquarters since the announcement was made on Tuesday.

One of those visitors got a vape pen while the other, a woman with a rescue dog currently on Prozac, received CBD doggy treats in lieu of the prescription medicine she can’t afford for the pooch.

Of course, there may be a good reason why the federal workers may not be attempting to score the free sensimilla.

Federal law currently prohibits government employees from using marijuana, even in states that have legalized the drug. A bill last year that would have changed the law did not make it to a vote.

The finding is true regardless of whether a state legalized medical marijuana

By Angela Chen@chengela  Jan 24, 2019, 1:11pm EST

Young people living in liberal states consume more marijuana, but have lower rates of marijuana dependence, according to a new study from Columbia University’s Mailman School of Public Health. Crucially, this finding is true regardless of whether the state legalized medical marijuana, suggesting that the broader political climate affects how people use the drug. It also serves as a reminder that the effects of legalization will look different in different states.

Right now, 33 states have legalized medical marijuana, while 10 have legalized recreational marijuana. As approval continues to grow, plenty of researchers are curious about how legalization will affect health outcomes. For the new study, published this week in the International Journal of Drug Policy, researchers cross-referenced drug use data from the National Survey on Drug Use and Health with information on how liberal or conservative a state is. (The “liberal” or “conservative” ranking came from the State Rank on Policy Liberalism Index, which looks at a state’s policies toward abortion access, taxes, collective bargaining, gun control, and federal assistance programs.)

The results found that these policies, which aren’t specifically related to cannabis, still have an impact on cannabis use, according to study author Morgan Philbin, a professor of sociomedical sciences at Columbia University. Though the study isn’t designed to look at how any one specific policy might influence cannabis outcomes, it’s still important for policymakers to realize that cannabis laws passed in different states could have different outcomes.

In general, people in both liberal and conservative states are consuming more marijuana. In a span of about eight years, ending in 2011, the percentage of people ages 18 to 25 living in liberal states consuming cannabis grew from 33 percent to about 37 percent. In contrast, the numbers for the same age group in conservative states went from about 25 percent to 26 percent.

Similarly, fewer people in both liberal and conservative states are struggling with cannabis use disorder. People with CUD experience withdrawal symptoms like mood and sleep problems if they don’t consume cannabis for a while, and can’t stop using it even if it negatively impacts their life. The rates of CUD fell to 17 percent from 20 percent in liberal states. However, CUD rates only fell to 18 percent from 22 percent in conservative states despite fewer people in conservative states using marijuana to begin with.

It’s unclear why we’re seeing this pattern, according to Philbin. It’s also important to note that the study only looked at associations; it doesn’t prove that living in a liberal state will make someone smoke more weed. Still, the big takeaway is that it’s important to see how marijuana legalization laws might lead to different outcomes and have different impacts based on the local political climate, she adds. For example, states may differ in factors like availability and stigma, which could change cannabis-related attitudes, which could lead to different health outcomes if a marijuana legalization law is passed. Next, Philbin’s team will do similar research with recreational cannabis laws and dive more into specific policies that might affect drug outcomes.